Table 4.
Individual disease score items’ univariable relation to blood composite scores.
| SIRI × 10−3 | NLR | MLR | PLR | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | Beta Coef. (95%). p | Beta Coef. (95%). p | Beta Coef. (95%), p | Beta Coef. (95%), p | |||||
| Katz Index | ||||||||||
| History of cerebritis (seizure or organic brain syndrome) | 12 | 6 | 0.4 (−0.02–1) | 0.064 | 0.5 (−0.03–1) | 0.064 | 0.06 (−0.02–0.1) | 0.16 | −25 (−61–11) | 0.18 |
| History of pulmonary disease | 10 | 5 | 0.4 (−0.05–1) | 0.086 | 0.3 (−0.3–1) | 0.39 | 0.1 (0.06–0.2) | 0.001 | 30 (−7–66) | 0.11 |
| Biopsy proven diffuse proliferative glomerulonephritis | 23 | 12 | −0.003 (−0.3–0.3) | 0.98 | −0.08 (−0.5–0.3) | 0.70 | −0.01 (−0.07–0.05) | 0.73 | −13 (−38–13) | 0.33 |
| 4–6 ARA criteria por SLE satisfied to date | 139 | 73 | −0.1 (−1–0.3) | 0.51 | −0.1 (−1–0.4) | 0.63 | −0.03 (−0.1–0.05) | 0.44 | 17 (−19–52) | 0.36 |
| 7 or more ARA criteria for SLE satisfied to date | 23 | 12 | 0.2 (−0.07–0.5) | 0.13 | 0.3 (−0.04–1) | 0.08 | 0.1 (0.05–0.2) | <0.001 | 16 (−9–40) | 0.22 |
| History of proteinuria (2+ or more) | 62 | 32 | 0.1 (−0.3–1) | 0.60 | −0.05 (−1–0.5) | 0.86 | −0.0003 (−0.08–0.08) | 0.99 | 1 (−34–36) | 0.95 |
| Lowest recorded hematocrit to date = 30–37% | 88 | 46 | −0.05 (−0.5–0.3) | 0.81 | 0.05 (−0.5–1) | 0.86 | −0.009 (−0.09–0.07) | 0.83 | 9 (−23–42) | 0.57 |
| Lowest recorded hematocrit to date < 30% | 47 | 25 | 0.1 (−0.1–0.3) | 0.26 | 0.1 (−0.2–0.4) | 0.37 | 0.06 (0.01–0.1) | 0.016 | 19 (0.1–38) | 0.049 |
| Highest recorded creatinine to date = 1.3–3 | 28 | 15 | 0.6 (0.1–1) | 0.020 | 0.5 (−0.2–1) | 0.18 | 0.03 (−0.08–0.1) | 0.57 | −27 (−72–19) | 0.25 |
| Highest recorded creatinine to date > 3 | 3 | 2 | 0.2 (−1–1) | 0.70 | −0.1 (−1–1) | 0.80 | −0.01 (−0.2–0.1) | 0.88 | −25 (−87–37) | 0.43 |
| SLEDAI | ||||||||||
| Seizures | 1 | 0 | −0.02 (−2–2) | 0.99 | −0.5 (−4–3) | 0.76 | −0.2 (−1–0.3) | 0.48 | −83 (−278–112) | 0.40 |
| Psychosis | 1 | 0 | −1 (−3–1) | 0.39 | −1 (−4–2) | 0.41 | −0.2 (−1–0.3) | 0.36 | −135 (−330–60) | 0.17 |
| Organic brain syndrome | 0 | 0 | - | - | - | - | ||||
| Visual disturbance | 1 | 0 | 0.4 (−2–3) | 0.70 | 2 (−1–5) | 0.20 | −0.09 (−1–0.4) | 0.71 | −122 (−317–73) | 0.22 |
| Cranial nerve disorder | 1 | 0 | −0.5 (−3–2) | 0.63 | −0.002 (−3–3) | 0.99 | −0.2 (−1–0.3) | 0.41 | 7 (−189–203) | 0.94 |
| Lupus headache | 1 | 0 | 0.04 (−2–2) | 0.97 | −1 (−4–2) | 0.50 | 0.3 (−0.2–1) | 0.24 | 57 (−138–253) | 0.56 |
| ACVA | 0 | 0 | - | - | - | - | ||||
| Vasculitis | 1 | 0 | 4 (1–6) | 0.001 | 4 (1–7) | 0.004 | 0.2 (−0.3–1) | 0.45 | 27 (−168–223) | 0.78 |
| Arthritis | 9 | 3 | −0.09 (−1–1) | 0.82 | 0.4 (−1–1) | 0.40 | 0.04 (−0.1–0.2) | 0.59 | 47 (−19–113) | 0.16 |
| Myositis | 0 | 0 | - | - | - | - | ||||
| Urinary cylinders | 7 | 3 | −0.2 (−1–1) | 0.70 | −0.5 (−2–1) | 0.42 | 0.1 (−0.06–0.3) | 0.21 | −57 (−138–23) | 0.16 |
| Hematuria | 16 | 6 | −0.3 (−1–0.3) | 0.35 | −0.3 (−1–1) | 0.50 | 0.06 (−0.06–0.2) | 0.31 | 24 (−27–77) | 0.35 |
| Proteinuria | 5 | 2 | 0.3 (−1–1) | 0.54 | −0.1 (−2–1) | 0.87 | −0.02 (−0.2–0.2) | 0.85 | −10 (−98–79) | 0.83 |
| Pyuria | 11 | 4 | −0.06 (−1–1) | 0.85 | −0.3 (−1–1) | 0.58 | −0.08 (−0.2–0.05) | 0.23 | −41 (−101–19) | 0.18 |
| Rash | 21 | 8 | −0.0006 (−1–1) | 0.99 | −0.05 (−1–1) | 0.88 | 0.02 (−0.09–0.1) | 0.77 | 14 (−31–58) | 0.55 |
| Alopecia | 11 | 4 | 0.3 (−0.3–1) | 0.32 | 0.3 (−1–1) | 0.55 | 0.07 (−0.07–0.2) | 0.35 | −17 (−77–44) | 0.59 |
| Mucosal ulcers | 14 | 5 | −0.06 (−1–1) | 0.86 | 0.3 (−1–1) | 0.56 | 0.1 (−0.03–0.2) | 0.14 | −1 (−61–60) | 0.98 |
| Pleurisy | 3 | 1 | −1 (−2–1) | 0.41 | 0.2 (−2–2) | 0.87 | −0.07 (−0.4–0.2) | 0.65 | 258 (123–393) | <0.001 |
| Pericarditis | 1 | 0 | −1 (−3–1) | 0.35 | −1 (−4–2) | 0.40 | −0.2 (−0.7–0.2) | 0.31 | −27 (−222–169) | 0.79 |
| Low complement | 76 | 28 | −0.05 (−0.4–0.3) | 0.75 | −0.09 (−1–0.3) | 0.68 | 0.04 (−0.03–0.1) | 0.26 | 7 (−20–34) | 0.62 |
| Elevated antiDNA | 85 | 31 | 0.1 (−0.2–0.4) | 0.45 | 0.3 (−0.1–1) | 0.19 | 0.09 (−0.05–0.07) | 0.78 | 20 (−6–46) | 0.14 |
| Fever | 2 | 1 | −1 (−2–1) | 0.48 | −0.4 (−3–2) | 0.71 | −0.09 (−0.4–0.2) | 0.59 | 110 (−28–247) | 0.12 |
| Thrombopenia | 10 | 4 | 0.1 (−1–1) | 0.70 | 1 (0.3–2) | 0.010 | 0.03 (−0.1–0.2) | 0.70 | −66 (−129–(−4)) | 0.038 |
| Leukopenia | 19 | 7 | −0.5 (−1–0.04) | 0.071 | −0.004 (−1–1) | 0.99 | 0.1 (−0.02–0.2) | 0.094 | 98 (156–143) | <0.001 |
| SLICC domains | ||||||||||
| Ocular | 63 | 22 | 0.1 (−0.2–0.4) | 0.56 | 0.06 (−0.4–1) | 0.79 | 0.0002 (−0.07–0.07) | 0.99 | −8 (−37–20) | 0.57 |
| Neuropsychiatric | 40 | 14 | 0.02 (−0.4–0.4) | 0.91 | 0.07 (−0.5–1) | 0.80 | 0.002 (−0.08–0.08) | 0.97 | −47 (−81–(−12)) | 0.008 |
| Renal | 28 | 10 | 0.1 (−0.3–1) | 0.67 | −0.2 (−1–0.4) | 0.55 | −0.005 (−0.1–0.09) | 0.92 | −25 (−64–14) | 0.21 |
| Pulmonary | 19 | 7 | −0.1 (−1–0.4) | 0.68 | −0.3 (−1–0.5) | 0.43 | 0.05 (−0.06–0.2) | 0.40 | 7 (−41–56) | 0.77 |
| Cardiovascular | 23 | 8 | −0.03 (−1–0.5) | 0.90 | −0.07 (−1–1) | 0.86 | 0.06 (−0.05–0.2) | 0.32 | 0.3 (−47–48) | 0.99 |
| Peripheral vascular | 34 | 12 | 0.2 (−0.2–1) | 0.38 | 0.3 (−0.3–1) | 0.30 | 0.1 (0.02–0.2) | 0.020 | 13 (−24–50) | 0.50 |
| Gastrointestinal | 28 | 10 | −0.1 (−1–0.3) | 0.56 | −0.3 (−1–0.3) | 0.34 | 0.03 (−0.06–0.1) | 0.51 | −19 (−59–21) | 0.35 |
| Musculoskeletal | 89 | 31 | 0.002 (−0.3–0.3) | 0.99 | 0.2 (−0.2–1) | 0.41 | 0.03 (−0.03–0.09) | 0.36 | 18 (−7–43) | 0.17 |
| Skin | 39 | 14 | 0.03 (−0.4–0.4) | 0.88 | −0.3 (−1–0.2) | 0.24 | 0.05 (−0.03–0.1) | 0.22 | −16 (−50–19) | 0.38 |
| Premature gonadal failure | 19 | 7 | −0.02 (−1–1) | 0.94 | 0.05 (−1–1) | 0.90 | −0.02 (−0.1–0.1) | 0.79 | 5 (−45–56) | 0.83 |
| Diabetes (regardless of treatment) | 18 | 6 | 0.003 (−1–1) | 0.99 | −0.3 (−1–0.5) | 0.42 | −0.09 (−0.2–0.03) | 0.14 | −40 (−90–10) | 0.11 |
| Malignancy (excluded dysplasia) | 11 | 4 | −1 (−1–0.2) | 0.14 | −1 (−2–0.2) | 0.13 | −0.1 (−0.3–0.01) | 0.066 | −18 (−84–48) | 0.60 |
History of pulmonary disease refers to the presence of lupus pneumonitis, pulmonary hemorrhage, or pulmonary hypertension. SLEDAI: Systemic Lupus Erythematosus Disease Activity Index. SLE: Systemic Lupus Erythematosus. SLICC: Systemic Lupus International Collaborating Clinics/American Colleague of Rheumatology Damage Index. The presence of a SLICC domain involvement if shown if the point in the domain is ≥1. See Supplementary Table S1. ARA: American Rheumatism Association. ACVA: acute cerebrovascular accident. SIRI: systemic inflammation response index. NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; MLR: monocyte-to-lymphocyte ratio. Significant p values are depicted in bold.